Home » Newsletters » The Carlat Psychiatry Report

The Carlat Psychiatry Report

Treatment of ADHD (September) | 2006

View Archived Issues

Daytrana: A Long and Winding Road to Approval

September 1, 2006

On April 6, 2006, the FDA announced the approval of Daytrana, a transdermal patch version of Ritalin (methylphenidate). While you wouldn’t know it by the gushy promotional copy on Daytrana’s website (www.daytrana.com), the Ritalin patch just barely squeaked through the FDA approval process. Read More

Sparlon and ADHD: The Power of a 7-Year Old

September 1, 2006

Rarely has a 7-year old with a rash caused the stock price of a major corporation to gyrate so dramatically. Read More

A Patient’s Perspective: The Value of an ADHD Diagnosis

September 1, 2006

Mr. H., now 49, was first diagnosed with ADHD at the age of 40, when he was evaluated at the suggestion of an old friend, a psychologist who had known him in grade school. Read More

Stimulants: The Case for Caution

September 1, 2006

Lawrence H. Diller, MD

Dr. Diller, as a behavioral pediatrician you certainly prescribe stimulants and other psychiatric medications to children, but at the same time you have spent much of your career speaking and writing about some the potential negative consequences of the excessive use of stimulants. You’ve also studied the history of stimulant use, and have thought about how this can inform our decisions now. Read More

Psychostimulants and ADHD

September 1, 2006

Recently three new psychostimulant formulations have been approved (Daytrana, the Ritalin patch, and Focalin XR), and one older medication received a new indication (Adderall XR is now indicated for adult ADHD). Read More